Spero Therapeutics
SPRO
44 hedge funds and large institutions have $119M invested in Spero Therapeutics in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
26% more funds holding
Funds holding: 35 → 44 (+9)
9% more capital invested
Capital invested by funds: $110M → $119M (+$9.35M)
2.86% more ownership
Funds ownership: 53.62% → 56.48% (+2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.93M |
| 2 |
BlackRock
New York
|
+$1.15M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$431K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$423K |
| 5 |
State Street
Boston,
Massachusetts
|
+$378K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$2.68M |
| 2 |
JP Morgan Chase
New York
|
-$1.51M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$421K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$356K |
| 5 |
Millennium Management
New York
|
-$163K |
SPRO Hedge Fund Activity: Q2 2018 in Review
44 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2018, worth a combined $119M — up 8.5% from $110M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SPRO positions and 3 closed out — a net gain of 9 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was Granahan Investment Management, opening a new position worth an estimated $1.93M. The largest seller was AWM Investment Company, cutting an estimated $2.68M.
- 44 institutional investors held Spero Therapeutics (SPRO) as of Q2 2018, up from 35 in Q1 2018.
- Funds reported $119M of Spero Therapeutics stock for Q2 2018, up 8.5% quarter-over-quarter.
- 12 funds opened new Spero Therapeutics positions in Q2 2018 and 3 closed out, a net change of +9 holders.
- The largest Spero Therapeutics buyer in Q2 2018 was Granahan Investment Management, an estimated $1.93M added.
- The largest Spero Therapeutics seller in Q2 2018 was AWM Investment Company, an estimated $2.68M sold.
Based on aggregated 13F filings for Q2 2018.